Imipenem

Imipenem (MK0787), a stable crystalline derivative of thienamycin, is an antibiotic and has the excellent activity against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria. Imipenem can be used for the research of carbapenem-nonsusceptible and P. aeruginosa biofilm infections[1][2][3].

Product Specifications

CAS Number

[64221-86-9]

Product Name Alternative

N-Formimidoyl thienamycin; MK0787

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/imipenem.html

Purity

99.89

Solubility

H2O : 11.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C(N12)=C(SCCNC=N)C[C@]2([H])[C@@H]([C@H](O)C)C1=O)O

Molecular Formula

C12H17N3O4S

Molecular Weight

299.35

Precautions

H302, H312, H332

References & Citations

[1]Johann Motsch, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis. 2020 Apr 15;70 (9) :1799-1808.|[2]F P Tally, et al. In vitro activity of N-formimidoyl thienamycin (MK0787) . Antimicrob Agents Chemother. 1980 Oct;18 (4) :642-4.|[3]Wang Hengzhuang, et al. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012 May;56 (5) :2683-90.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

β-lactam

Citation 01

Antimicrob Agents Chemother. 2023 Oct 18;67 (10) :e0052823.|Antimicrob Agents Chemother. 2024 Feb 7;68 (2) :e0133223.|Antimicrob Agents Chemother. 2024 Oct 29:e0094524.|Antimicrob Agents Chemother. 2025 May 23:e0024925.|Authorea. 2025 Sep 17.|Cell Host Microbe. 2024 May 13:S1931-3128 (24) 00137-9.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Eur J Clin Microbiol Infect Dis. 2025 Sep 29.|Future Microbiol. 2025 Oct 13:1-10.|Infect Drug Resist. 2025 Oct 4:18:5239-5247.|Int J Antimicrob Agents. 2022 Nov-Dec;60 (5-6) :106669.|Int J Antimicrob Agents. 2025 Jun 4:107550.|iScience. 2023 Oct 7;26 (11) :108158.|J Antimicrob Chemother. 2025 Nov 5:dkaf408.|J Clin Microbiol. 2025 Aug 20:e0084125.|Microbiol Spectr. 2023 Dec 12;11 (6) :e0304723.|Microbiol Spectr. 2025 May 19:e0307424.|Microorganisms. 2024 Mar 13;12 (3) :575.|Molecules. 2025 Mar 9;30 (6) :1224.|Nat Commun. 2023 Mar 22;14 (1) :1594.|Open Forum Infect Dis. 2023 Jan 27;10 (2) :ofad038.|Res Sq. 2024 Nov 26.|Vet Microbiol. 2024 May:292:110046.|Anim Dis. 2021;1 (1) :26.|Antibiotics (Basel) . 2021 Sep 14;10 (9) :1110.|Commun Biol. 2023 Aug 12;6 (1) :837.|Free Radic Biol Med. 2024 Aug 1:220:179-191.|iScience. 2025 Mar 28;28 (5) :112311. |J Antimicrob Chemother. 2020 Jul 1;75 (7) :1850-1858.|J Cachexia Sarcopenia Muscle. 2023 Jun;14 (3) :1424-1440.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Sci Rep. 2022 Oct 7;12 (1) :16814.